Nasdaq
$10.84▲ 0.18%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $915.8MShares out 84.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
5- 10.6After-hours26.10.07 05:054Ownership#●●●
Monte Rosa Therapeutics, Inc.
Matthew Bowen, an insider at Monte Rosa Therapeutics, Inc., filed a Form 4 on October 6, 2026, reporting changes in beneficial ownership of securities as of October 5, 2026. This filing formalizes the recent equity transaction by the reporting insider.…more
$10.84+0.18%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.1Pre-market26.10.01 20:388-KKey event
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics announced positive results from its Phase 1 GFORCE-1 study, showing that MRT-8102 achieved 80-90% NEK7 degradation and significantly reduced key inflammatory biomarkers in obese subjects with elevated CVD risk. The drug demonstrated a favorable safety profile, and the company plans to initiate Phase 2 trials for coronary artery disease and hidradenitis suppurativa in the first half of 2027.…more
$10.84+0.18%vs prev closeView filingShare - 9.8Pre-market26.09.08 20:028-KKey event
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics has initiated a Phase 2 clinical study for its VAV1-directed molecular glue degrader, MRT-6160, in patients with Sjögren’s disease in collaboration with Novartis. The company will receive a $50 million milestone payment from Novartis following the initiation of this study. Monte Rosa remains eligible for up to $2.1 billion in additional development, regulatory, and sales milestones under the existing agreement.…more
$10.84+0.18%vs prev closeView filingShare
4 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.2After-hours26.10.03 05:01#●●●#●●●
Monte Rosa Therapeutics Grants Equity Awards to New Hires
Monte Rosa Therapeutics has granted stock options and restricted stock units totaling approximately 105,875 shares to five new non-executive employees. This equity award serves as a material inducement for their employment under Nasdaq listing rules.…more
$10.84+0.18%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.1Regular26.10.02 01:44
●●●●●●●● ●●●●● ●●●●●●
Monte Rosa Therapeutics announced that its drug candidate MRT-8102 successfully reduced key inflammatory biomarkers in a Phase 1 clinical trial. The company plans to advance the treatment into three separate Phase 2 studies targeting cardiovascular and inflammatory conditions.…more
$10.84+0.18%vs prev closeShareBenzinga - 10.1Pre-market26.10.01 20:15
●●●●●●●● ●●●●● ●●●●●●
Monte Rosa's MRT-8102 demonstrated safety and successfully normalized key inflammatory biomarkers in a Phase 1 study for cardiovascular disease risk. The company plans to advance the drug into Phase 2 trials for conditions including coronary artery disease and gout.…more
$10.84+0.18%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report